Bruce R Schackman1, Ashley A Eggman1, Jared A Leff1, Megan Braunlin1, Uriel R Felsen2, Lisa Fitzpatrick3, Edward E Telzak4, Wafaa El-Sadr5, Bernard M Branson6. 1. Weill Cornell Medical College, Department of Healthcare Policy and Research, New York, NY. 2. Montefiore Medical Center, Division of Infectious Diseases, Bronx, NY. 3. United Medical Center, The Care Center, Washington, DC. 4. Bronx Lebanon Hospital Center, Bronx, NY. 5. Columbia University, Mailman School of Public Health, International Center for AIDS Care and Treatment Programs, New York, NY. 6. Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, Atlanta, GA.
Abstract
OBJECTIVE: The HIV Prevention Trials Network (HPTN) 065 trial sought to expand HIV screening of emergency department (ED) patients in Bronx, New York, and Washington, D.C. This study assessed the testing costs associated with different expansion processes and compared them with costs of a hypothetical optimized process. METHODS: Micro-costing studies were conducted in two participating EDs in each city that switched from point-of-care (POC) to rapid-result laboratory testing. In three EDs, laboratory HIV testing was only conducted for patients having blood drawn for clinical reasons; in the other ED, all HIV testing was conducted with laboratory testing. Costs were estimated through direct observation and interviews to document process flows, time estimates, and labor and materials costs. A hypothetical optimized process flow used minimum time estimates for each process step. National wage and fringe rates and local reagent costs were used to determine the average cost (excluding overhead) per completed nonreactive and reactive test in 2013 U.S. dollars. RESULTS: Laboratory HIV testing costs in the EDs ranged from $17.00 to $23.83 per completed nonreactive test, and POC testing costs ranged from $17.64 to $37.60; cost per completed reactive test ranged from $89.29 to $123.17. Costs of hypothetical optimized HIV testing with automated process steps were approximately 45% lower for nonreactive tests and 20% lower for reactive tests. The cost per ED visit to conduct expanded HIV testing in each hospital ranged from $1.21 to $3.96. CONCLUSION: An optimized process could achieve additional cost savings but would require an investment in electronic system interfaces to further automate testing processes.
OBJECTIVE: The HIV Prevention Trials Network (HPTN) 065 trial sought to expand HIV screening of emergency department (ED) patients in Bronx, New York, and Washington, D.C. This study assessed the testing costs associated with different expansion processes and compared them with costs of a hypothetical optimized process. METHODS: Micro-costing studies were conducted in two participating EDs in each city that switched from point-of-care (POC) to rapid-result laboratory testing. In three EDs, laboratory HIV testing was only conducted for patients having blood drawn for clinical reasons; in the other ED, all HIV testing was conducted with laboratory testing. Costs were estimated through direct observation and interviews to document process flows, time estimates, and labor and materials costs. A hypothetical optimized process flow used minimum time estimates for each process step. National wage and fringe rates and local reagent costs were used to determine the average cost (excluding overhead) per completed nonreactive and reactive test in 2013 U.S. dollars. RESULTS: Laboratory HIV testing costs in the EDs ranged from $17.00 to $23.83 per completed nonreactive test, and POC testing costs ranged from $17.64 to $37.60; cost per completed reactive test ranged from $89.29 to $123.17. Costs of hypothetical optimized HIV testing with automated process steps were approximately 45% lower for nonreactive tests and 20% lower for reactive tests. The cost per ED visit to conduct expanded HIV testing in each hospital ranged from $1.21 to $3.96. CONCLUSION: An optimized process could achieve additional cost savings but would require an investment in electronic system interfaces to further automate testing processes.
Authors: Ashley A Eggman; Daniel J Feaster; Jared A Leff; Matthew R Golden; Pedro C Castellon; Lauren Gooden; Tim Matheson; Grant N Colfax; Lisa R Metsch; Bruce R Schackman Journal: Sex Transm Dis Date: 2014-09 Impact factor: 2.830
Authors: Bruce R Schackman; Lisa R Metsch; Grant N Colfax; Jared A Leff; Angela Wong; Callie A Scott; Daniel J Feaster; Lauren Gooden; Tim Matheson; Louise F Haynes; A David Paltiel; Rochelle P Walensky Journal: Drug Alcohol Depend Date: 2012-09-09 Impact factor: 4.492
Authors: Bernard M Branson; H Hunter Handsfield; Margaret A Lampe; Robert S Janssen; Allan W Taylor; Sheryl B Lyss; Jill E Clark Journal: MMWR Recomm Rep Date: 2006-09-22
Authors: Stacey A Rizza; Robin J MacGowan; David W Purcell; Bernard M Branson; Zelalem Temesgen Journal: Mayo Clin Proc Date: 2012-09 Impact factor: 7.616
Authors: Jason S Haukoos; Jonathan D Campbell; Amy A Conroy; Emily Hopkins; Meggan M Bucossi; Comilla Sasson; Alia A Al-Tayyib; Mark W Thrun Journal: PLoS One Date: 2013-12-31 Impact factor: 3.240
Authors: Xia Lin; Patricia M Dietz; Vanessa Rodriguez; Deborah Lester; Paloma Hernandez; Lisa Moreno-Walton; Grant Johnson; Michelle M Van Handel; Jacek Skarbinski; Christine L Mattson; Dale Stratford; Lisa Belcher; Bernard M Branson Journal: MMWR Morb Mortal Wkly Rep Date: 2014-06-27 Impact factor: 17.586
Authors: Bernard M Branson; Pollyanna R Chavez; Brett Hanscom; Elizabeth Greene; Laura McKinstry; Kate Buchacz; Geetha Beauchamp; Theresa Gamble; Barry S Zingman; Edward Telzak; Tammey Naab; Lisa Fitzpatrick; Wafaa M El-Sadr Journal: Clin Infect Dis Date: 2018-05-02 Impact factor: 9.079
Authors: Anne M Neilan; Raphael J Landovitz; Mylinh H Le; Beatriz Grinsztejn; Kenneth A Freedberg; Marybeth McCauley; Nattanicha Wattananimitgul; Myron S Cohen; Andrea L Ciaranello; Meredith E Clement; Krishna P Reddy; Emily P Hyle; A David Paltiel; Rochelle P Walensky Journal: Ann Intern Med Date: 2022-02-01 Impact factor: 51.598
Authors: Martin Hoenigl; Megan Lo; Christopher J Coyne; Gabriel A Wagner; Jill Blumenthal; Kushagra Mathur; Lucy E Horton; Thomas C S Martin; Gary M Vilke; Susan J Little Journal: AIDS Care Date: 2021-11-27
Authors: Anne M Neilan; Richard Dunville; M Cheryl Bañez Ocfemia; Joshua A Salomon; Jordan A Francke; Alexander J B Bulteel; Li Yan Wang; Katherine K Hsu; Elizabeth A DiNenno; Rochelle P Walensky; Robert A Parker; Kenneth A Freedberg; Andrea L Ciaranello Journal: J Adolesc Health Date: 2018-01 Impact factor: 5.012
Authors: Anne M Neilan; Alexander J B Bulteel; Sybil G Hosek; Julia H A Foote; Kenneth A Freedberg; Raphael J Landovitz; Rochelle P Walensky; Stephen C Resch; Pooyan Kazemian; A David Paltiel; Milton C Weinstein; Craig M Wilson; Andrea L Ciaranello Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 9.079
Authors: Ethan D Borre; Emily P Hyle; A David Paltiel; Anne M Neilan; Paul E Sax; Kenneth A Freedberg; Milton C Weinstein; Rochelle P Walensky Journal: J Infect Dis Date: 2017-10-17 Impact factor: 7.759